Effect of HBV infection on biological activity of NK cells cultured in vitro

doi:10.3877/cma.j.issn.2095-3232.2020.03.016

Abstract

Abstract:

Objective

To investigate the effect of HBV infection on the biological activity of NK cells.

Methods

Peripheral blood samples were collected from 49 patients who received reinfusion of NK cells cultured in Lingnan Hospital of the Third Affiliated Hospital of Sun Yat-sen University from January 2018 to December 2018. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 30 patients were male and 19 female, aged 27-87 years old with a median age of 60 years old. Blood samples were divided into the HBV(+) and HBV(-) groups according to the incidence of HBV infection. CD3^-CD56⁺ NK cells and CD3⁺CD56⁺ NKT cells were proliferated and cultured .The percentage of NK and NKT cells was detected by flow cytometry. The cell activity rate and apoptosis rate were statistically compared between two groups by t test.

Results

The cell activity rate in the HBV(-) group was (94.4±1.2)%, significantly higher than (85.1±4.6)% in the HBV(+) group (t=2.146, P<0.05). The apoptosis rate in the HBV(-) group was (3.2±0.9)%, significantly lower than (11.6±4.1)% in the HBV(+) group (t=-2.220, P<0.05). The percentage of NK cells in the HBV(-) group was (55.8±4.4)%, significantly higher than (34.7±5.9)% in the HBV(+) group (t=2.889, P<0.05).

Conclusions

More NK cells can be obtained from HBV(-) patient-derived cells proliferated and cultured .

Key words: Natural killer cell, Hepatitis B virus, Cell culture techniques

Huining Cai, Yan Xu, Xiaoyan Chen, Weicai Chen, Xiaofang Zheng. Effect of HBV infection on biological activity of NK cells cultured in vitro[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(03): 274-277.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2020.03.016

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2020/V09/I03/274

Figures/Tables 2

References 20

[1]	赵雪，宋蕊．自然杀伤细胞在感染中的研究进展[J/CD]．中华实验和临床感染病杂志(电子版)，2019, 13(2):93-98.
[2]	吴玲，郜玉峰，苏菲．NK/NKT细胞在乙型肝炎发病机制中的研究进展[J]．国际流行病学传染病学杂志，2010, 37(1):64-67.
[3]	Miller JS. Therapeutic applications: natural killer cells in the clinic[J]. Hematology Am Soc Hematol Educ Program, 2013:247-253.
[4]	邹勇，郑常龙，杨小安．HBV-ACLF患者外周血和肝脏IL-32的表达水平与肝损伤的相关性[J]．新医学，2018, 49(2):94-98.
[5]	曾永秦，逄晓莉，汪笛，等．NK细胞在HIV感染中的作用:进展和展望[J]．传染病信息，2018, 31(6):566-571.
[6]	Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer[J]. Scientifica, 2014:205796.
[7]	Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells[J]. Adv Immunol, 2014(122): 91-128.
[8]	Dahlberg C, Sarhan D, Chrobok M, et al. Natural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity [J]. Front Immunol, 2015(6):605.
[9]	Chester C, Fritsch K, Kohrt HE. Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for cancer immunotherapy[J]. Front Immunol, 2015(6):601.
[10]	Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks[J]. Nat Rev Cancer, 2015, 16(1):7-19.
[11]	Li Y, Yin J, Li T, et al. NK cell-based cancer immunotherapy: from basic biology to clinical application[J]. Sci China Life Sci, 2015, 58(12):1233-1245.
[12]	刘琳琳，聂汉祥．恒定自然杀伤细胞在感染免疫中的作用研究进展[J]．疑难病杂志，2016, 15(5):546-549.
[13]	李文静，张栋，顾绍庆．自然杀伤细胞受体与人巨细胞病毒感染的研究进展[J]．国际儿科学杂志，2015, 42(4):377-380.
[14]	Benson DM Jr, Cohen AD, Jagannath S, et al. A phaseⅠtrial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma[J]. Clin Cancer Res, 2015, 21(18):4055-4061.
[15]	Hermanson DL, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity[J]. Front Immunol, 2015(6): 195.
[16]	Glienke W, Esser R, Priesner C, et al. Advantages and applications of CAR-expressing natural killer cells[J]. Front Pharmacol, 2015(6): 21.
[17]	Szmania S, Lapteva N, Garg T, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients[J]. J Immunother, 2015, 38(1):24-36.
[18]	Sakamoto N, Ishikawa T, Kokura S, et al. PhaseⅠclinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer[J]. J Transl Med, 2015(13):277.
[19]	Oyer JL, Pandey V, Igarashi RY, et al. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment[J]. Cytotherapy, 2016, 18(5):653-663.
[20]	Kottaridis PD, North J, Tsirogianni M, et al. Two-stage priming of allogeneic natural killer cells for the treatment of patients with acute myeloid leukemia: a phase Ⅰ trial[J]. PLoS One, 2015, 10(6): e0123416.

组别	例数	年龄（岁，±s）	性别（例）
组别	例数	年龄（岁，±s）	男	女
HBV（+）组	18	61±5	14	4	?
HBV（-）组	31	60±3	16	15	?
统计值	?	t=0.076	χ2=1.086
P值	?	0.939	0.391

组别	例数	年龄（岁，±s）	性别（例）
组别	例数	年龄（岁，±s）	男	女
HBV（+）组	18	61±5	14	4	?
HBV（-）组	31	60±3	16	15	?
统计值	?	t=0.076	χ2=1.086
P值	?	0.939	0.391

Please choose a citation manager

Content to export